APEX1 and pancreatic neoplasm: Numerous studies had demonstrated that APX3330 specifically inhibited APE1 REDOX signaling in a variety of tumor models in vitro and in vivo, including pancreatic cancer, leukemia, and malignant peripheral nerve sheath tumors (MPNSTs) [28].